Aerie pharmaceuticals announces presentations at the association for research in vision and ophthalmology annual meeting in denver, colorado, may 1-4, 2022

Durham, n.c.--(business wire)--aerie pharmaceuticals, inc. (nasdaq: aeri), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that fourteen abstracts related to aerie's rhopressa®/netarsudil, ar-15512 in dry eye and “rock'sters” anti-inflammatory programs will be presented at the association for research in vision and ophthalmology annual meeting (arvo 2022) in denver, colorado, may 1 through 4, 2022. gary
AERI Ratings Summary
AERI Quant Ranking